
|Articles|April 22, 2015
- Melanoma (Issue 4)
- Volume 4
- Issue 1
Comparing Two Doses of Ipilimumab
Author(s)Ahmad Tarhini, MD, PhD
Ahmad Tarhini, MD, PhD, associate professor, University of Pittsburgh School of Medicine, compares two doses of ipilimumab (Yervoy).
Ahmad Tarhini, MD, PhD, associate professor, University of Pittsburgh School of Medicine, compares two doses of ipilimumab (Yervoy).
<<<
Articles in this issue
almost 11 years ago
Unprecedented Response Rates Seen With Ipilimumab Plus Nivolumab in Melanomaalmost 11 years ago
Toxicity of Immunotherapies in Melanomaabout 11 years ago
New Standards Needed to Lessen Surgery Delays in Melanomaabout 11 years ago
Neoantigens for Personalized Immunotherapy May Boost Melanoma Treatmentabout 11 years ago
Gene Removal May Pose Future Treatment in Advanced Melanomaabout 11 years ago
The Development of T-VEC for Melanomaabout 11 years ago
The Role of Macrophages in BRAF Inhibitor Resistance






























